Friday, 9th February 36th Lorne Cancer Conference 2024

Pratiti Bandopadhayay & Dieter Henrik Heiland's Talks are Sponsored By: 

• The Evolution of pediatric gliomas - Pratiti Bandopadhayay
• Unravel the temporal and topographical tumor heterogeneity in Glioblastoma - Dieter Henrik Heiland
• Development of juvenile models of childhood cancers reveals age-specific immune signatures in early life tumor microenvironment - Omar OE Elaskalani
• Elucidating the role of FGFR1 alterations in pediatric low-grade gliomas - April A Apfelbaum
• Voltage-gated sodium channel blockers are a promising adjunct therapy for high-grade gliomas - Emily V Fletcher

• Targeting oncogenic drivers and stem cells in colorectal cancer - Frederic de Sauvage
• In vivo veritas - using CRISPR technologies in mice to unravel novel cancer driver alterations in the non-coding genome. - Daniel Schramek
• Putting Function Back into Paediatric Cancer Genomics – novel genomic features in childhood cancers - Paul Ekert
• Memory of stochastic single-cell apoptotic signalling promotes chemoresistance in neuroblastoma - David R Croucher
• Harnessing CRISPR-Cas13 for selective ablation of point-mutated oncogenes with single-nucleotide precision - Carolyn E Shembrey

Speaker 1: Anjana Narayanan, Ph.D.
Mapping the Future with Spatial Genomics

To truly understand cancer biology, researchers need easy-to-use tools that preserve the natural complexity of tissues while capturing the nuances of gene and protein expression. Vizgen’s in situ single-cell genomics MERSCOPE® Platform, built on multiplexed error robust in situ hybridization (MERFISH) technology, enables the direct profiling of the spatial organization of intact tissue with subcellular resolution.

Speaker 2: Dr Yunshun (Andy) Chen 
Exploring human breast cancer tissues with Vizgen MERSCOPE®

Breast cancer is the most commonly occurring cancer in women. In the last decade, our investigations into human breast cancer tumor heterogeneity and the tumour microenvironment have heavily relied on advanced technologies, including next-generation sequencing platforms and single-cell techniques. The latest advancements in single-cell technologies have enabled us to capture gene expression profiles at a cellular level. However, the emergence of spatial technologies introduces an additional dimension of spatial information, providing enhanced insights into the cellular diversity of human breast cancer within a spatial context. This workshop will showcase an application of spatial technology in examining human breast tumour samples, utilizing the Vizgen MERSCOPE® Platform. In particular, I will highlight a comprehensive bioinformatics analysis pipeline designed to address specific biological questions that could not be answered previously, such as the cell type co-localization and the cell-to-cell interaction.

Join us to learn about the latest advancements in cutting-edge 10x Genomics single cell and spatial technologies that can take your research from exploration to refinement. The workshop includes 2 invited speakers and 10x product updates, including Visium HD.
Our first speaker, Jazmina will share results of their advanced analyses of spatial proteogenomic technologies including Visium in reoccurring cancers and how her work establishes a clear path for incorporating spatial omics in clinical settings to facilitate treatment personalization.
Our next speaker, Raymond from WEHI will be talking about their data generated in-house and high resolution in situ analysis of the tissue microenvironment using Xenium.

Speaker 1: Jazmina Gonzalez Cruz, PhD
Deep spatial-omics to aid personalization of precision medicine in metastatic recurrent cancers

Speaker 2: Raymond Yip, PhD
High resolution in situ analysis of tissue microenvironment using Xenium

• The Mechanobiology of Microtubules: Understanding How Tumour Cells Survive Confined Spaces - Samantha Stehbens
• Developing engineered bacteria for tumour detection and treatment - Susan Woods
• Molecular profiling and testing matched therapeutic strategies in preclinical models aid treatment decision making for rare gynaecological cancers - Holly E Barker
• Rationalising the inclusion of HDAC inhibitors with standard-of-care chemotherapy for high-risk neuroblastoma - Monica Phimmachanh

Flash Talks

1. Selective inhibition of ROCK2 co-targets elements of the fibrotic and immune microenvironment to improve the overall anti-tumour response in models of advanced pancreatic cancer - Benjamin McLean

2. Systematic identification of cancer vulnerabilities engendered by germline variants - Sean Misek

3. Deciphering the response to temozolomide in heterogeneous glioblastoma populations - Zachery Moore

4. Characterization of fibroblast populations in mammary gland development and breast cancer - Rosa Pascual

5. Understanding Therapeutic Resistance Mechanisms and Immune Response in Cutaneous Melanoma: Implications for Precision Treatment - Riyaben P Patel

6. Dual epithelial and stromal targeting in triple negative breast cancer using ROCK2 inhibition - Daniel A Reed

7. Dual proteomic and transcriptomic screening reveals PCSK9 as a novel co-target in metastatic pancreatic ductal adenocarcinoma - Shona Ritchie

8. SRP19 and protein secretion machinery is a vulnerability in cancers with APC copy number loss - Xinqi Xi

• Systematic identification of cancer vulnerabilities engendered by germline variants - Sean Misek
• Deciphering the response to temozolomide in heterogeneous glioblastoma populations - Zachery Moore
• SRP19 and protein secretion machinery is a vulnerability in cancers with APC copy number loss - Xinqi Xi
• Characterization of fibroblast populations in mammary gland development and breast cancer - Rosa Pascual
• Dual proteomic and transcriptomic screening reveals PCSK9 as a novel co-target in metastatic pancreatic ductal adenocarcinoma. - Shona Ritchie
• Selective inhibition of ROCK2 co-targets elements of the fibrotic and immune microenvironment to improve the overall anti-tumour response in models of advanced pancreatic cancer - Benjamin McLean
• Understanding Therapeutic Resistance Mechanisms and Immune Response in Cutaneous Melanoma: Implications for Precision Treatment - Riyaben P Patel
• Dual epithelial and stromal targeting in triple negative breast cancer using ROCK2 inhibition   - Daniel A Reed
• Investigating ribosome-targeting therapies for the treatment of relapsed/resistant multiple myeloma - Kezia Gitareja
• Targeting the nucleoli as a strategy to treat ovarian cancer - Shalini Sundramurthi Chelliah
• The nucleolar stress response leads to replication stress that can be harnessed to treat PAPRi-resistant ovarian cancer - Ruofei Liu
• High dietary fructose facilitates liver tumorigenesis in mice via bile acid metabolism - Frances L. Byrne
• Co-targeting dihydroorotate dehydrogenase and cell survival proteins in brain cancer to improve patient outcomes - Diane Moujalled
• Targeting androgen signaling in glioblastoma: a novel biomarker and therapeutic approach - Sofia RE Mason
• Transcriptional reprogramming of tumour associated macrophages in glioblastoma - Samuel S. Widodo
• ALK+ anaplastic large cell lymphoma in children (NOT ATTENDING) - Amar Ranjan
• Radiosensitising paediatric medulloblastoma cells by exploiting the dna damage response pathway - Jacob Byrne
• Targeting Peroxidasin in the stroma of breast cancer - Kaitlin Wyllie
• ZEB1: More than meets the EMT - Cerys McCool
• Modulating mRNA translation machinery to prevent and treat chemotherapy-resistant triple-negative breast cancer - Heloisa Helena HH Milioli
• Characterising the Mutational Landscape and Recurrent Somatic Driver Events to Uncover Therapeutic Susceptibilities in Pancreatic Cancer - Sehrish Kanwal
• Therapeutic potential of targeting epigenetic deregulation in pancreatic cancer - Johana Luhur
• Drug screening of cancer cell lines and organoids to identify novel compounds for treatment of ovarian carcinosarcoma. - Andrew W Farrell
• Fidelity assessment reveals prevailing mutations in DIY vectors made across the globe - Thomas Leung
• SPARC as a key regulator of breast cancer metastasis and resistance to therapy - Nicole Laurencia Yuwono
• Spatial architecture of high-grade glioma reveals tumour heterogeneity within distinct domains  - Joel JD Moffet
• Investigating metabolic drivers of cancer cell plasticity in triple-negative breast cancer - Carley Purcell
• The Centre of Excellence in Cellular Immunotherapy at Peter Mac - Jane Oliaro
• Incorporating tissue dimensionality and healthy brain tissue mimetics into preclinical assessments to improve prediction of clinical efficacy for brain cancer therapy - Geraldine O'Neill
• Bayesian inference for copy number intra-tumoral heterogeneity from single-cell RNA-sequencing data (NOT ATTENDING) - PuXue Qiao
• Primary high throughput screening for modulators of autophagy as drugs for cancer treatment using the powerful imaging reagent CalRexin^TM:pHrodo Red. - Peter J Wookey
• Investigating CD8+ T cell peripheral tolerance in colorectal cancer - Avraham Travers
• Peritoneal tumour DNA in gastroesophageal cancer – metanalysis and a pilot study   - Zexi Allan
• The ribotoxic stress response regulates tumour immune escape via MHC-I transcript decay - Keziah E Ting
• Virtual multiplexing of lung cancer cells using multi-modal microscopy and vision transformers for characterisation of epithelial-mesenchymal plasticity - Andrew Gunawan
• Comprehensive assessment of homologous recombination deficiency by whole genome and transcriptome sequencing for personalised cancer management - Layla Zhu
• Identification of a novel NTRK2 activating internal tandem duplication in paediatric CNS neuroblastoma - Lauren M Brown
• Exploring if tumor cell proliferation affects their sensitivity to the BCL2 inhibitor venetoclax - Michelle Jahja
• Investigation of the effect of takinib on oncogenic transformation in granulosa cell tumour-derived cell lines - Trang Minh Tran
• Ex vivo tumour drug response profiling identifies novel rational treatment options for paediatric cancer patients - Emmy Dolman
• Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma - Vasilios Panagopoulos
• Comprehensive analysis of immune cell multi-omics in cancer patients who are experiencing immune-related adverse events (NOT ATTENDING) - Dmitrii Shek
• Evolution of multiclonality in head and neck squamous cell carcinomas - Guy Lyons
• Investigating a novel matrisomal target in PC to reduce fibrosis and improve standard-of-care chemotherapy - Jessie Zhu
• Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq. - Michael Trpceski
• Role of glia maturation factor beta (GMFβ), an actin depolymerising factor, in neuroblastoma differentiation - David D Eisenstat
• Paediatric Glioma Histone H3.3 K27M/G34R Mutations Drive Abnormalities in Phase-Separated PML Nuclear Bodies. - Lee Wong
• Targeting the fibrotic microenvironment in pancreatic cancer via Porcupine inhibition - Sean Porazinski
• Phosphoproteomic profiling for novel target identification in childhood sarcomas: Paving the road towards improved outcomes for relapsed and metastatic osteosarcoma - Callum Perkins
• Exploiting the dna damage response to develop personalised treatments for high-risk sarcoma in children - Larissa Volken
• Targeting replication stress using a CHK1 inhibitor combination promotes anti-tumour immune responses which can be enhanced by reducing suppression from tumour-associated myeloid cells - Zhen Zeng
• Tuning chimeric antigen receptor (CAR)-T cell functions by manipulating receptor structure - Ashleigh Davey
• Exploring Tumour-Specific Fluorescent Probe in Oesophago-Gastric Malignancy - Mike Bozin
• Pro-malignant interactions between clones in head and neck squamous cell carcinomas - Natnicha Ketchaikosol
• A multi-omic approach for the detection of melanoma brain metastasis - Desiree Sexauer